Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

home / medcast-videos / faricimab-versus-high-dose-aflibercept-for-the-treatment-of-neovascular-amd-and-dme

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

Faricimab Versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

EP. 1: Faricimab Versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME

Paul Hahn, MD, PhD, FASRS;Michael Cohen, MD, FAAO;Jennifer Lim, MD, FARVO, FASRS
November 27th 2023

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.

© 2024 MJH Life Sciences

All rights reserved.